Trial Profile

An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination With Glofitamab in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapolsertib (Primary) ; Glofitamab; Obinutuzumab
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms JASPIS-01

26 Mar 2025 According to a Ryvu Therapeutics media release, company announced that the first patient has been dosed in the JASPIS-01 study.
13 Mar 2025 According to a Ryvu Therapeutics media release, The JASPIS-01 study was initiated in Q4 2024, currently awaiting enrollment of the first patient, which is still expected in Q1 2025. The study will commence at clinical sites in Poland with ongoing efforts to expand to additional EU and non-EU countries.
16 Dec 2024 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com